PEOPLE - Syneron Medical makes appointments:
This article was originally published in Clinica
Executive Summary
Medical aesthetic device manufacturer Syneron Medical (Yokneam, Israel) has appointed Dan Suesskind and Michael Anghel to its board of directors, serving as both independent directors, and as external directors (for Israeli law purposes). Mr Suesskind is CFO of Teva Pharmaceutical Industries, a generic drug company. Dr Anghel is president and CEO of the Israel Capital Markets and Investments Corporation.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.